Health Product Manufacturers and Innovators COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.

NAM perspectives Pub Date : 2022-01-18 DOI:10.31478/202201b
M. Mammen, Vasant Narasimhan, R. Kuntz, F. Lewis-Hall, Mojdeh Poul, A. Schechter
{"title":"Health Product Manufacturers and Innovators COVID-19 Impact Assessment: Lessons Learned and Compelling Needs.","authors":"M. Mammen, Vasant Narasimhan, R. Kuntz, F. Lewis-Hall, Mojdeh Poul, A. Schechter","doi":"10.31478/202201b","DOIUrl":null,"url":null,"abstract":"United States health care spending consumes nearly a fifth of the GDP [1]. While, in many respects, the U.S. health care system is enviable and highly innovative, it is also characterized by elements of ineffectiveness, inefficiency, and inequity. These aspects, resulting from pre-existing vulnerabilities within the system and interactions between the various stakeholders, were acutely highlighted by the COVID-19 pandemic. As health product manufacturers and innovators (HPMI) took steps to mitigate the immediate crisis and simultaneously begin to develop a longer-term sustainable solution, six common themes arose as areas for transformational change: support for science, data sharing, supply chain resiliency, stockpiling, and surge capacity, regulatory and reimbursement clarity and flexibility, public- and private-sector coordination and communication, and minimizing substandard care offerings. Within these categories, the authors of this paper suggest policy priorities to increase the effectiveness, efficiency, and equity of the HPMI sector and writ large across the U.S. health care system. These priorities call for increased scientific funding to diversify the pipeline for research and development, strengthening the nation’s public health infrastructure, building and maintaining “ever warm” manufacturing capacity and related stockpiles, instituting efficient and effective regulatory and reimbursement frameworks that promote innovation and creativity, devising structures and processes that enable more efficient collaboration and more effective communication to the public, and implementing rewards that incentivize desired behaviors among stakeholders. This assessment draws from the collective experience of the authors to provide a perspective for the diagnostics, hospital supplies and equipment, medical devices, therapeutics, and vaccines segments. While the authors of this paper agree on a common set of key policies, sub-sector-specific nuances are important to consider when putting any action priority into effect. With thoughtful implementation, these policies will enable a quicker, more robust response to future pandemics and enhance the overall performance of the U.S. health care system.","PeriodicalId":74236,"journal":{"name":"NAM perspectives","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NAM perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31478/202201b","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

United States health care spending consumes nearly a fifth of the GDP [1]. While, in many respects, the U.S. health care system is enviable and highly innovative, it is also characterized by elements of ineffectiveness, inefficiency, and inequity. These aspects, resulting from pre-existing vulnerabilities within the system and interactions between the various stakeholders, were acutely highlighted by the COVID-19 pandemic. As health product manufacturers and innovators (HPMI) took steps to mitigate the immediate crisis and simultaneously begin to develop a longer-term sustainable solution, six common themes arose as areas for transformational change: support for science, data sharing, supply chain resiliency, stockpiling, and surge capacity, regulatory and reimbursement clarity and flexibility, public- and private-sector coordination and communication, and minimizing substandard care offerings. Within these categories, the authors of this paper suggest policy priorities to increase the effectiveness, efficiency, and equity of the HPMI sector and writ large across the U.S. health care system. These priorities call for increased scientific funding to diversify the pipeline for research and development, strengthening the nation’s public health infrastructure, building and maintaining “ever warm” manufacturing capacity and related stockpiles, instituting efficient and effective regulatory and reimbursement frameworks that promote innovation and creativity, devising structures and processes that enable more efficient collaboration and more effective communication to the public, and implementing rewards that incentivize desired behaviors among stakeholders. This assessment draws from the collective experience of the authors to provide a perspective for the diagnostics, hospital supplies and equipment, medical devices, therapeutics, and vaccines segments. While the authors of this paper agree on a common set of key policies, sub-sector-specific nuances are important to consider when putting any action priority into effect. With thoughtful implementation, these policies will enable a quicker, more robust response to future pandemics and enhance the overall performance of the U.S. health care system.
健康产品制造商和创新者COVID-19影响评估:经验教训和迫切需求。
美国的医疗保健支出占国内生产总值的近五分之一[1]。尽管在许多方面,美国的医疗保健系统令人羡慕且具有高度创新性,但它也具有无效、低效和不公平的特点。新冠肺炎大流行突出强调了这些方面,这些方面源于系统内预先存在的脆弱性以及不同利益相关者之间的互动。随着健康产品制造商和创新者采取措施缓解眼前的危机,同时开始制定更长期的可持续解决方案,六个共同的主题成为转型变革的领域:支持科学、数据共享、供应链弹性、储备和激增能力、监管和报销的明确性和灵活性,公共和私营部门的协调和沟通,最大限度地减少不合格的护理服务。在这些类别中,本文作者提出了提高HPMI部门的有效性、效率和公平性的政策优先事项,并在整个美国医疗保健系统中广泛应用。这些优先事项要求增加科学资金,使研发渠道多样化,加强国家公共卫生基础设施,建设和保持“持续升温”的制造能力和相关库存,建立高效有效的监管和报销框架,促进创新和创造力,设计结构和流程,实现更高效的合作和更有效的公众沟通,并实施奖励,激励利益相关者的期望行为。这项评估借鉴了作者的集体经验,为诊断、医院用品和设备、医疗器械、治疗和疫苗领域提供了一个视角。虽然本文的作者就一套共同的关键政策达成了一致,但在实施任何行动优先事项时,考虑特定子部门的细微差别是很重要的。通过深思熟虑的实施,这些政策将能够更快、更有力地应对未来的流行病,并提高美国医疗保健系统的整体绩效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信